Chemours Q3 Earnings Lag Estimates Amid Operational Disruptions

Chemours (CC) reported mixed Q3 results, with adjusted earnings per share of $0.20 missing consensus estimates, despite net sales of $1.495 billion, a 1% year-over-year decline, slightly beating expectations. Operational disruptions in Titanium Technologies and an outage at Advanced Performance Materials contributed to a 3% decline in adjusted EBITDA to $195 million, though the Thermal & Specialized Solutions segment posted strong 20% sales growth driven by Opteon demand. For Q4, the company projects a sequential net sales decline of 10-15% due to seasonality, with adjusted EBITDA forecast between $130 million and $160 million, and maintains a Zacks #5 (Strong Sell) rating.

Analysis

Chemours (CC) reported a mixed third quarter for 2025, with adjusted earnings per share of $0.20 missing the Zacks Consensus Estimate of $0.24, despite net sales of $1.495 billion, which slightly surpassed the $1.492.2 million estimate. While net income improved significantly to $60 million from a $32 million loss year-over-year, overall sales still saw a 1% decline, primarily due to a 3% volume drop.
Adjusted EBITDA decreased 3% year-over-year to $195 million, largely impacted by increased costs from resolved operational disruptions in the Titanium Technologies business and an outage at the Advanced Performance Materials’ Washington Works site. This was partially mitigated by robust performance in the Thermal & Specialized Solutions segment, which saw revenues climb 20% to $560 million, driven by an 8% volume increase from Opteon demand and 11% higher pricing.
The company's fourth-quarter outlook projects a sequential net sales decline of 10-15% due to seasonality and anticipates Adjusted EBITDA between $130 million and $160 million. This cautious guidance, coupled with the stock's 33.9% decline over the past year and a current Zacks Rank #5 (Strong Sell), indicates persistent challenges and a pessimistic market sentiment surrounding CC.

Key Decisions for Investors

• Investors should exercise caution given the missed adjusted EPS, declining EBITDA, and negative Q4 outlook.
• Closely monitor the impact of resolved operational disruptions on future profitability and cash generation.
• Consider the strong performance of the Thermal & Specialized Solutions segment as a potential long-term driver but weigh it against broader segment weaknesses and industrial market headwinds.